Innovative Alternative to LNPs for mRNA Therapeutics, in vivo-jetRNA®+, Polyplus-transfection

Supplier: Polyplus-transfection
jetRNA®
101000122 101000122
CA76579-662EA 2233.14 CAD
76579-662 CA76579-662
Innovative Alternative to LNPs for mRNA Therapeutics, in vivo-jetRNA®+, Polyplus-transfection
Transfection Reagents
In vivo-jetRNA®+ is a ready-to-use, efficient and stable lipid-based transfection reagent optimized for in vivo mRNA delivery.

  • Efficient: 100% mRNA encapsulation leading to comparable LNP delivery results
  • Time saving: Ready-to-use reagent that does not require formulation equipment
  • Stable: Maintain liposome size using low to high mRNA concentration over time
  • Universal: Target any organ/tissue using various administration routes
  • Safe: Maintain healthy animals and organs

In vivo-jetRNA®+ is a lipid-based transfection reagent composed of preformed liposomes specifically developed to deliver mRNA in vivo. In vivo-jetRNA®+ has been carefully optimized by Polyplus and can be used with a simple and straightforward protocol without any formulation step (contrary to lipid nanoparticles). This reagent can be used to target unique or multiple organs, by using systemic injection routes, in various animal models (mice, rat, etc.).

Certifications: Polyplus® has been an ISO 9001 accredited company since 2002. Since then this certification has been successfully renewed every 3 years.
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR